申请人:HOFFMANN LA ROCHE
公开号:WO2010040661A1
公开(公告)日:2010-04-15
The invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl or is lower alkyl substituted by hydroxy; R2 is hydrogen, lower alkoxy or lower alkyl; R3/R4 are independently from each other hydrogen, halogen, lower alkyl, C(O)O-lower alkyl, OR', NR''R"', lower alkyl substituted by halogen or hydroxy, or is phenyl or benzyl, optionally substituted by one or two halogen atoms; R' is lower alkyl, or is phenyl, benzyl or pyridinyl, which rings are optionally substituted by one or more halogen, lower alkyl or lower alkyl substituted by fluoro; R'' is hydrogen or lower alkyl; R'" is lower alkyl, lower alkyl substituted by one or two hydroxy groups, CH(CH2OH)-phenyl, or is -(CH2)2O-lower alkyl, or is phenyl substituted by halogen, or R'' and R''' form together with the N-atom to which they are attached a heterocyclic ring, optionally substituted by one or more lower alkyl, CH2C(O)O-lower alkyl, or by CH2C(O)OH; Ar is a fϊve-membered heteroaryl group; or to pharmaceutically active acid addition salts. It has been found that the present compounds of formula (I) are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
本发明涉及式(I)的化合物,其中R1为氢、低烷基或被羟基取代的低烷基;R2为氢、低烷氧基或低烷基;R3/R4分别独立地为氢、卤素、低烷基、C(O)O-低烷基、OR'、NR''R'''、被卤素或羟基取代的低烷基,或为苯基或苄基,可选择性地被一个或两个卤素原子取代;R'为低烷基,或为苯基、苄基或吡啶基,这些环可选择性地被一个或多个卤素、低烷基或被氟取代的低烷基取代;R''为氢或低烷基;R'''为低烷基,被一个或两个羟基取代的低烷基,CH(CH2OH)-苯基,或为-(CH2)2O-低烷基,或为被卤素取代的苯基,或R''和R'''与它们连接的N原子一起形成一个杂环,可选择性地被一个或多个低烷基、CH2C(O)O-低烷基或CH2C(O)OH取代;Ar为五元杂芳基;或为药用活性酸盐。已发现,式(I)的这些化合物是淀粉样β的调节剂,因此它们可能对治疗或预防与β-淀粉在大脑中沉积相关的疾病有用,特别是阿尔茨海默病,以及其他疾病,如脑淀粉样血管病、家族性脑出血伴淀粉样变性、荷兰型多梗塞性痴呆、拳击性痴呆和唐氏综合征。